Journal Article

Early empirical glycopeptide therapy for patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia: impact on the outcome

Chi-Tai Fang, Wen-Yi Shau, Po-Ren Hsueh, Yee-Chun Chen, Jann-Tay Wang, Chien-Ching Hung, Loreen Y. L. Huang and Shan-Chwen Chang

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 57, issue 3, pages 511-519
Published in print March 2006 | ISSN: 0305-7453
Published online January 2006 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dkl006
Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

Objectives: To evaluate whether appropriate early empirical glycopeptide therapy improves outcomes of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia.

Methods: We retrospectively collected the data for all adult patients with confirmed MRSA bacteraemia diagnosed and treated at National Taiwan University Hospital during the period 1 April 1997–31 March 2001, and followed their survival up to three years. The main outcome measures were MRSA-related death and all-cause mortality.

Results: There were 77 MRSA-related deaths among 162 patients. There was no statistically significant difference in MRSA-related deaths between patients receiving glycopeptides before or within 48 h after blood culture (n = 43) (55%, 18/33, non-septic shock group; 90%, 9/10, septic shock group) or those whose glycopeptide therapy was begun more than 48 h after blood culture (n = 119) (37%, 40/107, non-septic shock group; 83%, 10/12, septic shock group) (P = 0.11 and 1.00, respectively). The outcome measure of all-cause mortality from 30 days to 3 years yields similar results. Multivariate logistic regression analysis and Cox analysis showed that the length of delay (daily increment) between blood culture sampling and start of glycopeptide therapy did not have a statistically significant impact on MRSA-related death or all-cause 30-day mortality after adjusting for the effect of other variables [adjusted odds ratio 0.99, 95% confidence interval (95% CI) 0.88–1.12; adjusted hazard ratio 0.87, 95% CI 0.74–1.02, respectively).

Conclusions: The hypothesis that earlier empirical use of glycopeptide therapy reduces mortality in patients with hospital-acquired MRSA bacteraemia was not supported.

Keywords: vancomycin; teicoplanin; nosocomial infections; prognosis

Journal Article.  5277 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.